An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
NCT01932528
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoid Syndrome
Interventions
DRUG:
500 mg [14C]-LX1606
Sponsor
Lexicon Pharmaceuticals